Proposed Local Coverage Determination (LCD) - MolDX: Signatera™ and MinimalResidual Disease Testing for Colorectal Cancer (DL38290)

Written By Laura Tramontozzi

View Letter

Laura Tramontozzi
Previous

Medicare Coverage of Innovative Technology & Definition of “Reasonable & Necessary”
Next

MolDX Local Coverage Determination (DL38043)